ARS Pharmaceuticals, Inc. (SPRY) Stock: Price, Forecast & Analyst Target
ARS Pharmaceuticals, Inc. (SPRY) — MoonshotScore 14/100 (Weak band), calculated Nov 18, 2026. Price $2.96 (-11.90%), as of the Nov 20, 2026 trading session; market cap $298M.
Educational signal · not a buy or sell recommendation · How to read this
ARS Pharmaceuticals, Inc. · SPRY · NASDAQ
ARS Pharmaceuticals, Inc. Their lead product, Neffy, aims to provide a needle-free alternative to traditional epinephrine injections.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · ARS Pharmaceuticals (SPRY)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, a fragile balance sheet and stalling growth, and it’s expensive on top — broad distress, a capital-preservation call, not a value entry. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Strained; Valuation: Bubble; Growth Durability: Shrinking; Momentum: Slipping.
- EPS beat 0 of the last 4 reports
- Altman Z -3.04 · Piotroski F 2
Holding back: weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 14 | Weak | |
| 14 | Weak | |
| 14 | Weak | |
| 14 | Weak | |
| 14 | Weak | |
| 14 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $2.96 | |
| Change on the day | -11.90% | |
| 52-week range | $2.44 – $13.15 | |
| Market capitalisation | $298M | — |
| Shares traded on the day | 2.78M |
Price & events
Other perspectives
Council score for ARS Pharmaceuticals (SPRY): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is ARS Pharmaceuticals (SPRY), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. ARS Pharmaceuticals, Inc. (SPRY) is listed on NASDAQ. It employs 198 people and is led by Donn Casale. The market values it at $298M.
What do the latest results show for ARS Pharmaceuticals (SPRY)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $33M | -$51M | -$0.52 (diluted) |
| Q4 FY2025 | $28M | -$41M | — |
| Q1 FY2026 | $23M | -$61M | -$0.61 (diluted) |
| Q2 FY2026 | $34M | -$62M | -$0.63 (diluted) |
What are the financial strengths and risks for ARS Pharmaceuticals (SPRY)?
Short answer
What is holding it back is weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z -3.04 · Piotroski F 2. Trailing ratios: ROA -39.5% · current ratio 3.25.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -3.04 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What should you watch next at ARS Pharmaceuticals (SPRY)?
Short answer · as of
Current published price targets run low $15.00 · high $15.00 · consensus $15.00 · median $15.00 against a quoted price of $2.96 (as of Nov 20, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does ARS Pharmaceuticals compare with its peers?
Short answer
ARS Pharmaceuticals's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.45 Nov 19, 2026 | $475M | 91 5-pillar Nov 18, 2026 | |
| $8.76 Nov 20, 2026 | $521M | 91 5-pillar Nov 18, 2026 | |
| $2.90 Nov 20, 2026 | $245M | 90 5-pillar Nov 18, 2026 | |
| $40.09 Nov 20, 2026 | $755M | 88 5-pillar Nov 18, 2026 | |
| $10.92 Nov 20, 2026 | $99.3M | 82 5-pillar Nov 18, 2026 | |
| $3.69 Nov 19, 2026 | $160M | 72 5-pillar Nov 18, 2026 | |
| $1.84 Nov 20, 2026 | $174M | 69 5-pillar Nov 18, 2026 | |
| $11.54 Nov 20, 2026 | $817M | 69 5-pillar Nov 18, 2026 | |
| $9.19 Nov 20, 2026 | $540M | 68 5-pillar Nov 18, 2026 | |
| $30.43 Nov 20, 2026 | $1.02B | 64 5-pillar Nov 18, 2026 | |
| $7.98 Nov 20, 2026 | $780M | 63 5-pillar Nov 18, 2026 | |
| $10.02 Nov 20, 2026 | $148M | 61 5-pillar Nov 18, 2026 | |
| ARS Pharmaceuticals (SPRY) — this page | $2.96 | $298M | 14 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $15.00 – $15.00
- Consensus target
- $15.00
- Median target
- $15.00
Consensus record · Captured .
Measured against a quoted price of $2.96 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 2, 2026
- Transactions
- 17
- Identified insiders
- 14
- Purchases
- 0
- Sales
- 2
- Other transactions
- 15
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held SPRY in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Third Point | Dan Loeb | Q3 2026 | 0.09% | $4.31M | Held, unchanged |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about ARS Pharmaceuticals (SPRY)?
Investor Questions: SPRY Stock
These answers are editorial: 1 of these 9 answers is drawn from the SPRY research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for SPRY?
SPRY carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is SPRY a good stock to buy?
Stock Expert AI does not rate SPRY buy, sell or hold. ARS Pharmaceuticals, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the SPRY stock price today?
The last price recorded for ARS Pharmaceuticals, Inc. (SPRY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the SPRY price target?
The analyst consensus price target for ARS Pharmaceuticals, Inc. (SPRY), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the main risks for SPRY?
The main risks for ARS Pharmaceuticals include regulatory risk, commercialization risk, and competition risk. Regulatory risk stems from the uncertainty of obtaining FDA approval for Neffy, as well as the potential for delays or unexpected requirements.
What are the key factors to evaluate for SPRY?
ARS Pharmaceuticals, Inc. (SPRY) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Not financial advice.
How frequently does SPRY data refresh on this page?
SPRY's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven SPRY's recent stock price performance?
ARS Pharmaceuticals, Inc. (SPRY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel needle-free epinephrine delivery system. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SPRY overvalued or undervalued right now?
ARS Pharmaceuticals, Inc. (SPRY) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 17 figures on this page — 10 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com